CA2740389A1 - 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors - Google Patents

Info

Publication number

CA2740389A1

CA2740389A1 CA2740389A CA2740389A CA2740389A1 CA 2740389 A1 CA2740389 A1 CA 2740389A1 CA 2740389 A CA2740389 A CA 2740389A CA 2740389 A CA2740389 A CA 2740389A CA 2740389 A1 CA2740389 A1 CA 2740389A1

Authority

CA

Canada

Prior art keywords

oxo

methyl

hydroquinazolin

dihydroquinazolin

dichlorophenyl

Prior art date

2008-10-15

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 108010087894 Fatty acid desaturases Proteins 0.000 title claims abstract description 67
• 102000016553 Stearoyl-CoA Desaturase Human genes 0.000 title claims abstract description 66
• 239000003112 inhibitor Substances 0.000 title abstract description 13
• 150000001875 compounds Chemical class 0.000 claims abstract description 295
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 56
• 201000010099 disease Diseases 0.000 claims abstract description 41
• 208000008589 Obesity Diseases 0.000 claims abstract description 15
• 235000020824 obesity Nutrition 0.000 claims abstract description 15
• 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 13
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 10
• 201000011510 cancer Diseases 0.000 claims abstract description 7
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 410
• 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 243
• DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 231
• -1 heteroaryl amide Chemical class 0.000 claims description 202
• 125000000217 alkyl group Chemical group 0.000 claims description 125
• 150000003857 carboxamides Chemical class 0.000 claims description 114
• 125000003118 aryl group Chemical group 0.000 claims description 86
• 125000001072 heteroaryl group Chemical group 0.000 claims description 83
• 125000001424 substituent group Chemical group 0.000 claims description 64
• 238000000034 method Methods 0.000 claims description 57
• 229910052739 hydrogen Inorganic materials 0.000 claims description 51
• 125000000623 heterocyclic group Chemical group 0.000 claims description 46
• 239000001257 hydrogen Substances 0.000 claims description 45
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 43
• 125000003342 alkenyl group Chemical group 0.000 claims description 42
• 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 38
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 36
• KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 36
• 125000000304 alkynyl group Chemical group 0.000 claims description 34
• 125000003545 alkoxy group Chemical group 0.000 claims description 31
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 31
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 29
• 150000002431 hydrogen Chemical group 0.000 claims description 29
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 27
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 24
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 24
• 125000002947 alkylene group Chemical group 0.000 claims description 22
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 21
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 19
• 125000002950 monocyclic group Chemical group 0.000 claims description 18
• 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 16
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
• JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical group O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 14
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 14
• 150000003839 salts Chemical class 0.000 claims description 14
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 13
• 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 12
• 125000004423 acyloxy group Chemical group 0.000 claims description 12
• 125000000547 substituted alkyl group Chemical group 0.000 claims description 12
• 125000004442 acylamino group Chemical group 0.000 claims description 11
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 11
• 125000004104 aryloxy group Chemical group 0.000 claims description 10
• 125000005553 heteroaryloxy group Chemical group 0.000 claims description 10
• 239000008194 pharmaceutical composition Substances 0.000 claims description 10
• 208000032928 Dyslipidaemia Diseases 0.000 claims description 9
• 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 8
• 208000017170 Lipid metabolism disease Diseases 0.000 claims description 8
• 241000124008 Mammalia Species 0.000 claims description 7
• 125000003107 substituted aryl group Chemical group 0.000 claims description 7
• 101100240528 Caenorhabditis elegans nhr-23 gene Proteins 0.000 claims description 6
• 206010022489 Insulin Resistance Diseases 0.000 claims description 6
• 208000032109 Transient ischaemic attack Diseases 0.000 claims description 6
• 230000002401 inhibitory effect Effects 0.000 claims description 6
• LRZFEBJUJIQVDQ-UHFFFAOYSA-N methyl 2-(dimethylamino)acetate Chemical compound COC(=O)CN(C)C LRZFEBJUJIQVDQ-UHFFFAOYSA-N 0.000 claims description 6
• JMSDMPBPEGROHI-JTQLQIEISA-N n-[3-[(1s)-1-(3,4-dichlorophenyl)ethyl]-4-oxoquinazolin-7-yl]-2-hydroxyacetamide Chemical compound C1([C@H](C)N2C(C3=CC=C(NC(=O)CO)C=C3N=C2)=O)=CC=C(Cl)C(Cl)=C1 JMSDMPBPEGROHI-JTQLQIEISA-N 0.000 claims description 6
• 201000010875 transient cerebral ischemia Diseases 0.000 claims description 6
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
• 125000002619 bicyclic group Chemical group 0.000 claims description 5
• 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 5
• 230000003247 decreasing effect Effects 0.000 claims description 5
• 150000002148 esters Chemical class 0.000 claims description 5
• JMSDMPBPEGROHI-SNVBAGLBSA-N n-[3-[(1r)-1-(3,4-dichlorophenyl)ethyl]-4-oxoquinazolin-7-yl]-2-hydroxyacetamide Chemical compound C1([C@@H](C)N2C(C3=CC=C(NC(=O)CO)C=C3N=C2)=O)=CC=C(Cl)C(Cl)=C1 JMSDMPBPEGROHI-SNVBAGLBSA-N 0.000 claims description 5
• TZIVVDOZEHUUFW-UHFFFAOYSA-N n-[3-[(3,4-dichlorophenyl)methyl]-4-oxoquinazolin-6-yl]acetamide Chemical compound O=C1C2=CC(NC(=O)C)=CC=C2N=CN1CC1=CC=C(Cl)C(Cl)=C1 TZIVVDOZEHUUFW-UHFFFAOYSA-N 0.000 claims description 5
• SRCWQMIQDMSABI-UHFFFAOYSA-N 2-hydroxy-n-[4-oxo-3-[(3-phenylphenyl)methyl]quinazolin-6-yl]acetamide Chemical compound O=C1C2=CC(NC(=O)CO)=CC=C2N=CN1CC(C=1)=CC=CC=1C1=CC=CC=C1 SRCWQMIQDMSABI-UHFFFAOYSA-N 0.000 claims description 4
• AJRHFFKPSZMWPO-UHFFFAOYSA-N 3-[(3,4-dichlorophenyl)methyl]-n-(2-methoxyethyl)-4-oxoquinazoline-7-carboxamide Chemical compound C=1C(C(=O)NCCOC)=CC=C(C2=O)C=1N=CN2CC1=CC=C(Cl)C(Cl)=C1 AJRHFFKPSZMWPO-UHFFFAOYSA-N 0.000 claims description 4
• 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 4
• 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 4
• 206010020772 Hypertension Diseases 0.000 claims description 4
• NWFYTGSYBSYCOU-UHFFFAOYSA-N [2-[[3-[(3-chloro-4-fluorophenyl)methyl]-4-oxoquinazolin-6-yl]amino]-2-oxoethyl] acetate Chemical compound O=C1C2=CC(NC(=O)COC(=O)C)=CC=C2N=CN1CC1=CC=C(F)C(Cl)=C1 NWFYTGSYBSYCOU-UHFFFAOYSA-N 0.000 claims description 4
• 125000004663 dialkyl amino group Chemical group 0.000 claims description 4
• 239000008103 glucose Substances 0.000 claims description 4
• AYWPACLSVIRDFY-UHFFFAOYSA-N n-(3-benzyl-4-oxoquinazolin-6-yl)-2-hydroxyacetamide Chemical compound O=C1C2=CC(NC(=O)CO)=CC=C2N=CN1CC1=CC=CC=C1 AYWPACLSVIRDFY-UHFFFAOYSA-N 0.000 claims description 4
• UXWAENYXNXUWHG-SNVBAGLBSA-N n-[3-[(1r)-1-[4-chloro-3-(trifluoromethyl)phenyl]ethyl]-4-oxoquinazolin-6-yl]-2-hydroxyacetamide Chemical compound C1([C@@H](C)N2C(C3=CC(NC(=O)CO)=CC=C3N=C2)=O)=CC=C(Cl)C(C(F)(F)F)=C1 UXWAENYXNXUWHG-SNVBAGLBSA-N 0.000 claims description 4
• PLLMZYHSSGPIPW-UHFFFAOYSA-N n-[3-[(3,4-difluorophenyl)methyl]-4-oxoquinazolin-6-yl]-2-hydroxyacetamide Chemical compound O=C1C2=CC(NC(=O)CO)=CC=C2N=CN1CC1=CC=C(F)C(F)=C1 PLLMZYHSSGPIPW-UHFFFAOYSA-N 0.000 claims description 4
• XBWXBBIHXFRYOE-UHFFFAOYSA-N n-[3-[(3,4-dimethylphenyl)methyl]-4-oxoquinazolin-6-yl]-2-hydroxyacetamide Chemical compound C1=C(C)C(C)=CC=C1CN1C(=O)C2=CC(NC(=O)CO)=CC=C2N=C1 XBWXBBIHXFRYOE-UHFFFAOYSA-N 0.000 claims description 4
• WYCXEKKLBAECDV-UHFFFAOYSA-N n-[3-[(4-chlorophenyl)methyl]-4-oxoquinazolin-6-yl]-2-hydroxyacetamide Chemical compound O=C1C2=CC(NC(=O)CO)=CC=C2N=CN1CC1=CC=C(Cl)C=C1 WYCXEKKLBAECDV-UHFFFAOYSA-N 0.000 claims description 4
• UVNYGTQVNXJYOX-UHFFFAOYSA-N n-[3-[1-(3,4-dichlorophenyl)ethyl]-4-oxoquinazolin-6-yl]-2-hydroxyacetamide Chemical compound C1=NC2=CC=C(NC(=O)CO)C=C2C(=O)N1C(C)C1=CC=C(Cl)C(Cl)=C1 UVNYGTQVNXJYOX-UHFFFAOYSA-N 0.000 claims description 4
• IBALPTMGUFTXFW-UHFFFAOYSA-N n-[3-[1-(3,4-dichlorophenyl)propyl]-4-oxoquinazolin-6-yl]-2-hydroxyacetamide Chemical compound C1=NC2=CC=C(NC(=O)CO)C=C2C(=O)N1C(CC)C1=CC=C(Cl)C(Cl)=C1 IBALPTMGUFTXFW-UHFFFAOYSA-N 0.000 claims description 4
• GWQNYIBHBLIXEJ-UHFFFAOYSA-N n-[3-[2-(2,4-dichlorophenyl)ethyl]-4-oxoquinazolin-6-yl]-2-hydroxyacetamide Chemical compound O=C1C2=CC(NC(=O)CO)=CC=C2N=CN1CCC1=CC=C(Cl)C=C1Cl GWQNYIBHBLIXEJ-UHFFFAOYSA-N 0.000 claims description 4
• TVJUKCVZGFXXNM-UHFFFAOYSA-N n-[3-[2-(2,5-dichlorophenoxy)ethyl]-4-oxoquinazolin-6-yl]-2-hydroxyacetamide Chemical compound O=C1C2=CC(NC(=O)CO)=CC=C2N=CN1CCOC1=CC(Cl)=CC=C1Cl TVJUKCVZGFXXNM-UHFFFAOYSA-N 0.000 claims description 4
• QKYJBOLLEGURPD-UHFFFAOYSA-N n-[3-[2-(2-chlorophenoxy)ethyl]-4-oxoquinazolin-6-yl]-2-hydroxyacetamide Chemical compound O=C1C2=CC(NC(=O)CO)=CC=C2N=CN1CCOC1=CC=CC=C1Cl QKYJBOLLEGURPD-UHFFFAOYSA-N 0.000 claims description 4
• NATUMQMREIDLNK-UHFFFAOYSA-N n-[3-[2-(2-chlorophenoxy)ethyl]-4-oxoquinazolin-7-yl]-2-hydroxyacetamide Chemical compound C=1C(NC(=O)CO)=CC=C(C2=O)C=1N=CN2CCOC1=CC=CC=C1Cl NATUMQMREIDLNK-UHFFFAOYSA-N 0.000 claims description 4
• VAJCDSSORKOZGI-UHFFFAOYSA-N n-[3-[2-(3-chlorophenoxy)ethyl]-4-oxoquinazolin-6-yl]-2-hydroxyacetamide Chemical compound O=C1C2=CC(NC(=O)CO)=CC=C2N=CN1CCOC1=CC=CC(Cl)=C1 VAJCDSSORKOZGI-UHFFFAOYSA-N 0.000 claims description 4
• REYFHLSLYNRKPX-UHFFFAOYSA-N n-[3-[2-(3-chlorophenyl)ethyl]-4-oxoquinazolin-6-yl]-2-hydroxyacetamide Chemical compound O=C1C2=CC(NC(=O)CO)=CC=C2N=CN1CCC1=CC=CC(Cl)=C1 REYFHLSLYNRKPX-UHFFFAOYSA-N 0.000 claims description 4
• GCVCPWKQNCZKDL-UHFFFAOYSA-N n-[3-[2-(4-chlorophenoxy)ethyl]-4-oxoquinazolin-6-yl]-2-hydroxyacetamide Chemical compound O=C1C2=CC(NC(=O)CO)=CC=C2N=CN1CCOC1=CC=C(Cl)C=C1 GCVCPWKQNCZKDL-UHFFFAOYSA-N 0.000 claims description 4
• HMSNCISXSUECEB-UHFFFAOYSA-N n-[3-[2-(4-chlorophenyl)ethyl]-4-oxoquinazolin-6-yl]-2-hydroxyacetamide Chemical compound O=C1C2=CC(NC(=O)CO)=CC=C2N=CN1CCC1=CC=C(Cl)C=C1 HMSNCISXSUECEB-UHFFFAOYSA-N 0.000 claims description 4
• IYONCBOKLGDXMJ-UHFFFAOYSA-N n-[3-[2-[(2,5-dichlorophenyl)sulfonylamino]ethyl]-4-oxoquinazolin-6-yl]-2-hydroxyacetamide Chemical compound O=C1C2=CC(NC(=O)CO)=CC=C2N=CN1CCNS(=O)(=O)C1=CC(Cl)=CC=C1Cl IYONCBOKLGDXMJ-UHFFFAOYSA-N 0.000 claims description 4
• RORPUVRZXYZASA-UHFFFAOYSA-N n-[3-[3-(2,3-dichlorophenoxy)propyl]-4-oxoquinazolin-6-yl]-2-hydroxyacetamide Chemical compound O=C1C2=CC(NC(=O)CO)=CC=C2N=CN1CCCOC1=CC=CC(Cl)=C1Cl RORPUVRZXYZASA-UHFFFAOYSA-N 0.000 claims description 4
• ZYBXKSWALPWWQQ-UHFFFAOYSA-N n-[3-[3-(2,5-dichlorophenoxy)propyl]-4-oxoquinazolin-6-yl]-2-hydroxyacetamide Chemical compound O=C1C2=CC(NC(=O)CO)=CC=C2N=CN1CCCOC1=CC(Cl)=CC=C1Cl ZYBXKSWALPWWQQ-UHFFFAOYSA-N 0.000 claims description 4
• KVZYMEFWOBVJHL-UHFFFAOYSA-N n-[3-[3-(2,5-dichlorophenoxy)propyl]-4-oxoquinazolin-7-yl]-2-hydroxyacetamide Chemical compound C=1C(NC(=O)CO)=CC=C(C2=O)C=1N=CN2CCCOC1=CC(Cl)=CC=C1Cl KVZYMEFWOBVJHL-UHFFFAOYSA-N 0.000 claims description 4
• MFMVQNBXIYJAHT-UHFFFAOYSA-N n-[3-[3-(2-chlorophenoxy)propyl]-4-oxoquinazolin-6-yl]-2-hydroxyacetamide Chemical compound O=C1C2=CC(NC(=O)CO)=CC=C2N=CN1CCCOC1=CC=CC=C1Cl MFMVQNBXIYJAHT-UHFFFAOYSA-N 0.000 claims description 4
• OLWNATBKNXAMAW-UHFFFAOYSA-N n-[3-[3-(2-chlorophenyl)propyl]-4-oxoquinazolin-6-yl]-2-hydroxyacetamide Chemical compound O=C1C2=CC(NC(=O)CO)=CC=C2N=CN1CCCC1=CC=CC=C1Cl OLWNATBKNXAMAW-UHFFFAOYSA-N 0.000 claims description 4
• ZPNOFXLIUYCILJ-UHFFFAOYSA-N n-[3-[3-(2-fluorophenoxy)propyl]-4-oxoquinazolin-7-yl]-2-hydroxyacetamide Chemical compound C=1C(NC(=O)CO)=CC=C(C2=O)C=1N=CN2CCCOC1=CC=CC=C1F ZPNOFXLIUYCILJ-UHFFFAOYSA-N 0.000 claims description 4
• AUMYINXCQGKYQO-UHFFFAOYSA-N n-[3-[3-(4-chlorophenoxy)propyl]-4-oxoquinazolin-6-yl]-2-hydroxyacetamide Chemical compound O=C1C2=CC(NC(=O)CO)=CC=C2N=CN1CCCOC1=CC=C(Cl)C=C1 AUMYINXCQGKYQO-UHFFFAOYSA-N 0.000 claims description 4
• KJKRJIJOIPCXSK-UHFFFAOYSA-N n-[3-[3-[(2,5-dichlorophenyl)sulfonylamino]propyl]-4-oxoquinazolin-6-yl]-2-hydroxyacetamide Chemical compound O=C1C2=CC(NC(=O)CO)=CC=C2N=CN1CCCNS(=O)(=O)C1=CC(Cl)=CC=C1Cl KJKRJIJOIPCXSK-UHFFFAOYSA-N 0.000 claims description 4
• ZYHAOOUJIRAVKM-UHFFFAOYSA-N n-[3-[3-[2-chloro-5-(trifluoromethyl)phenoxy]propyl]-4-oxoquinazolin-6-yl]-2-hydroxyacetamide Chemical compound O=C1C2=CC(NC(=O)CO)=CC=C2N=CN1CCCOC1=CC(C(F)(F)F)=CC=C1Cl ZYHAOOUJIRAVKM-UHFFFAOYSA-N 0.000 claims description 4
• BAJKEXWWSBUXGL-UHFFFAOYSA-N n-[3-[4-(2,5-dichlorophenoxy)butyl]-4-oxoquinazolin-6-yl]-2-hydroxyacetamide Chemical compound O=C1C2=CC(NC(=O)CO)=CC=C2N=CN1CCCCOC1=CC(Cl)=CC=C1Cl BAJKEXWWSBUXGL-UHFFFAOYSA-N 0.000 claims description 4
• VRZJMJLEEDFBAO-UHFFFAOYSA-N n-[3-[5-(2,5-dichlorophenoxy)pentyl]-4-oxoquinazolin-6-yl]-2-hydroxyacetamide Chemical compound O=C1C2=CC(NC(=O)CO)=CC=C2N=CN1CCCCCOC1=CC(Cl)=CC=C1Cl VRZJMJLEEDFBAO-UHFFFAOYSA-N 0.000 claims description 4
• IDYGCGYCHOUWQB-UHFFFAOYSA-N n-[3-[[4-chloro-3-(trifluoromethyl)phenyl]methyl]-4-oxoquinazolin-6-yl]-2-hydroxyacetamide Chemical compound O=C1C2=CC(NC(=O)CO)=CC=C2N=CN1CC1=CC=C(Cl)C(C(F)(F)F)=C1 IDYGCGYCHOUWQB-UHFFFAOYSA-N 0.000 claims description 4
• DTWKOBGWCSHUPS-UHFFFAOYSA-N n-[3-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-4-oxoquinazolin-6-yl]-2-hydroxyacetamide Chemical compound O=C1C2=CC(NC(=O)CO)=CC=C2N=CN1CC1=CC=C(F)C(C(F)(F)F)=C1 DTWKOBGWCSHUPS-UHFFFAOYSA-N 0.000 claims description 4
• MMKMXVBTEKTDST-JOCHJYFZSA-N (2r)-n-[3-[(3,4-dichlorophenyl)methyl]-4-oxoquinazolin-6-yl]-2-hydroxy-3-phenylpropanamide Chemical compound C([C@@H](O)C(=O)NC=1C=C2C(=O)N(CC=3C=C(Cl)C(Cl)=CC=3)C=NC2=CC=1)C1=CC=CC=C1 MMKMXVBTEKTDST-JOCHJYFZSA-N 0.000 claims description 3
• LJELBFFGTXYBQG-NRFANRHFSA-N (2s)-n-[3-[(3,4-dichlorophenyl)methyl]-4-oxoquinazolin-6-yl]-2-hydroxy-2-phenylacetamide Chemical compound O=C([C@@H](O)C=1C=CC=CC=1)NC(C=C1C2=O)=CC=C1N=CN2CC1=CC=C(Cl)C(Cl)=C1 LJELBFFGTXYBQG-NRFANRHFSA-N 0.000 claims description 3
• MMKMXVBTEKTDST-QFIPXVFZSA-N (2s)-n-[3-[(3,4-dichlorophenyl)methyl]-4-oxoquinazolin-6-yl]-2-hydroxy-3-phenylpropanamide Chemical compound C([C@H](O)C(=O)NC=1C=C2C(=O)N(CC=3C=C(Cl)C(Cl)=CC=3)C=NC2=CC=1)C1=CC=CC=C1 MMKMXVBTEKTDST-QFIPXVFZSA-N 0.000 claims description 3
• PXJFUCIUENRSIV-JOCHJYFZSA-N (3r)-n-[3-[(3,4-dichlorophenyl)methyl]-4-oxoquinazolin-6-yl]-3-hydroxy-3-phenylpropanamide Chemical compound C([C@@H](O)C=1C=CC=CC=1)C(=O)NC(C=C1C2=O)=CC=C1N=CN2CC1=CC=C(Cl)C(Cl)=C1 PXJFUCIUENRSIV-JOCHJYFZSA-N 0.000 claims description 3
• PXJFUCIUENRSIV-QFIPXVFZSA-N (3s)-n-[3-[(3,4-dichlorophenyl)methyl]-4-oxoquinazolin-6-yl]-3-hydroxy-3-phenylpropanamide Chemical compound C([C@H](O)C=1C=CC=CC=1)C(=O)NC(C=C1C2=O)=CC=C1N=CN2CC1=CC=C(Cl)C(Cl)=C1 PXJFUCIUENRSIV-QFIPXVFZSA-N 0.000 claims description 3
• QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 claims description 3
• MVEBVZSYYNMUPL-UHFFFAOYSA-N 2,5-dichloro-n-[2-[6-[(2-hydroxyacetyl)amino]-4-oxoquinazolin-3-yl]ethyl]benzamide Chemical compound O=C1C2=CC(NC(=O)CO)=CC=C2N=CN1CCNC(=O)C1=CC(Cl)=CC=C1Cl MVEBVZSYYNMUPL-UHFFFAOYSA-N 0.000 claims description 3
• ZFQYHUXDDOLXRV-UHFFFAOYSA-N 2-[[3-[(3,4-dichlorophenyl)methyl]-4-oxoquinazolin-6-yl]amino]-2-oxoacetic acid Chemical compound O=C1C2=CC(NC(=O)C(=O)O)=CC=C2N=CN1CC1=CC=C(Cl)C(Cl)=C1 ZFQYHUXDDOLXRV-UHFFFAOYSA-N 0.000 claims description 3
• KEBVMJAQZXAOEQ-UHFFFAOYSA-N 2-amino-n-[3-[(3,4-dichlorophenyl)methyl]-4-oxoquinazolin-6-yl]acetamide Chemical compound O=C1C2=CC(NC(=O)CN)=CC=C2N=CN1CC1=CC=C(Cl)C(Cl)=C1 KEBVMJAQZXAOEQ-UHFFFAOYSA-N 0.000 claims description 3
• BDYFZXYBWKZOPY-UHFFFAOYSA-N 2-hydroxy-n-[3-(naphthalen-2-ylmethyl)-4-oxoquinazolin-6-yl]acetamide Chemical compound C1=CC=CC2=CC(CN3C=NC4=CC=C(C=C4C3=O)NC(=O)CO)=CC=C21 BDYFZXYBWKZOPY-UHFFFAOYSA-N 0.000 claims description 3
• HNJZSHJKTIKCMX-UHFFFAOYSA-N 2-hydroxy-n-[3-(naphthalen-2-ylmethyl)-4-oxoquinazolin-7-yl]acetamide Chemical compound C1=CC=CC2=CC(CN3C=NC=4C(C3=O)=CC=C(C=4)NC(=O)CO)=CC=C21 HNJZSHJKTIKCMX-UHFFFAOYSA-N 0.000 claims description 3
• ZWZRBCCUBALXBX-UHFFFAOYSA-N 2-hydroxy-n-[3-[2-hydroxy-3-(2-methylphenoxy)propyl]-4-oxoquinazolin-6-yl]acetamide Chemical compound CC1=CC=CC=C1OCC(O)CN1C(=O)C2=CC(NC(=O)CO)=CC=C2N=C1 ZWZRBCCUBALXBX-UHFFFAOYSA-N 0.000 claims description 3
• KURQHGQZLPQQKS-UHFFFAOYSA-N 2-hydroxy-n-[3-[3-(2-methylphenoxy)propyl]-4-oxoquinazolin-6-yl]acetamide Chemical compound CC1=CC=CC=C1OCCCN1C(=O)C2=CC(NC(=O)CO)=CC=C2N=C1 KURQHGQZLPQQKS-UHFFFAOYSA-N 0.000 claims description 3
• NBTQJOXFKTUWAW-UHFFFAOYSA-N 2-hydroxy-n-[4-oxo-3-(2-phenylethyl)quinazolin-6-yl]acetamide Chemical compound O=C1C2=CC(NC(=O)CO)=CC=C2N=CN1CCC1=CC=CC=C1 NBTQJOXFKTUWAW-UHFFFAOYSA-N 0.000 claims description 3
• XXYOJKVAQJJWBH-UHFFFAOYSA-N 2-hydroxy-n-[4-oxo-3-(3-phenoxypropyl)quinazolin-6-yl]acetamide Chemical compound O=C1C2=CC(NC(=O)CO)=CC=C2N=CN1CCCOC1=CC=CC=C1 XXYOJKVAQJJWBH-UHFFFAOYSA-N 0.000 claims description 3
• INSJUSFBALZMRM-UHFFFAOYSA-N 2-hydroxy-n-[4-oxo-3-(3-phenylpropyl)quinazolin-6-yl]acetamide Chemical compound O=C1C2=CC(NC(=O)CO)=CC=C2N=CN1CCCC1=CC=CC=C1 INSJUSFBALZMRM-UHFFFAOYSA-N 0.000 claims description 3
• CJWNFVRHXXKSSX-UHFFFAOYSA-N 2-hydroxy-n-[4-oxo-3-[3-[2-(trifluoromethyl)phenoxy]propyl]quinazolin-6-yl]acetamide Chemical compound O=C1C2=CC(NC(=O)CO)=CC=C2N=CN1CCCOC1=CC=CC=C1C(F)(F)F CJWNFVRHXXKSSX-UHFFFAOYSA-N 0.000 claims description 3
• QSNDZZLNZWKAHB-UHFFFAOYSA-N 2-hydroxy-n-[4-oxo-3-[3-[[2-(trifluoromethyl)phenyl]sulfonylamino]propyl]quinazolin-6-yl]acetamide Chemical compound O=C1C2=CC(NC(=O)CO)=CC=C2N=CN1CCCNS(=O)(=O)C1=CC=CC=C1C(F)(F)F QSNDZZLNZWKAHB-UHFFFAOYSA-N 0.000 claims description 3
• 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 3
• 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 3
• 125000005975 2-phenylethyloxy group Chemical group 0.000 claims description 3
• ARJNHXXVYRQJFB-UHFFFAOYSA-N 3-[(3,4-dichlorophenyl)methyl]-4-oxo-n-(2-phenoxyethyl)quinazoline-7-carboxamide Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1C(=O)C2=CC=C(C(=O)NCCOC=3C=CC=CC=3)C=C2N=C1 ARJNHXXVYRQJFB-UHFFFAOYSA-N 0.000 claims description 3
• APLCAWDYNWTGSR-UHFFFAOYSA-N 3-[(3,4-dichlorophenyl)methyl]-n-methyl-4-oxoquinazoline-7-carboxamide Chemical compound C=1C(C(=O)NC)=CC=C(C2=O)C=1N=CN2CC1=CC=C(Cl)C(Cl)=C1 APLCAWDYNWTGSR-UHFFFAOYSA-N 0.000 claims description 3
• ULZIBTBULAXSCE-UHFFFAOYSA-N 3-[(4-chlorophenyl)methyl]-n-(2-hydroxyethyl)-4-oxoquinazoline-7-carboxamide Chemical compound C=1C(C(=O)NCCO)=CC=C(C2=O)C=1N=CN2CC1=CC=C(Cl)C=C1 ULZIBTBULAXSCE-UHFFFAOYSA-N 0.000 claims description 3
• MGHQWCLUVAGVFK-UHFFFAOYSA-N 3-[(4-chlorophenyl)methyl]-n-(2-methoxyethyl)-4-oxoquinazoline-7-carboxamide Chemical compound C=1C(C(=O)NCCOC)=CC=C(C2=O)C=1N=CN2CC1=CC=C(Cl)C=C1 MGHQWCLUVAGVFK-UHFFFAOYSA-N 0.000 claims description 3
• SHJBXYZPUFWDMV-UHFFFAOYSA-N 3-[(4-chlorophenyl)methyl]-n-[(4-fluorophenyl)methyl]-4-oxoquinazoline-7-carboxamide Chemical compound C1=CC(F)=CC=C1CNC(=O)C1=CC=C2C(=O)N(CC=3C=CC(Cl)=CC=3)C=NC2=C1 SHJBXYZPUFWDMV-UHFFFAOYSA-N 0.000 claims description 3
• BYILTFWWHCOZOG-UHFFFAOYSA-N 3-[(4-chlorophenyl)methyl]-n-methyl-4-oxoquinazoline-7-carboxamide Chemical compound C=1C(C(=O)NC)=CC=C(C2=O)C=1N=CN2CC1=CC=C(Cl)C=C1 BYILTFWWHCOZOG-UHFFFAOYSA-N 0.000 claims description 3
• 201000001320 Atherosclerosis Diseases 0.000 claims description 3
• 208000002249 Diabetes Complications Diseases 0.000 claims description 3
• 206010012655 Diabetic complications Diseases 0.000 claims description 3
• 208000032382 Ischaemic stroke Diseases 0.000 claims description 3
• 208000018262 Peripheral vascular disease Diseases 0.000 claims description 3
• 208000017442 Retinal disease Diseases 0.000 claims description 3
• 206010038923 Retinopathy Diseases 0.000 claims description 3
• 208000006011 Stroke Diseases 0.000 claims description 3
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
• WFPYLTJBIPXIMX-UHFFFAOYSA-N [2-[[3-[(3,4-difluorophenyl)methyl]-4-oxoquinazolin-6-yl]amino]-2-oxoethyl] acetate Chemical compound O=C1C2=CC(NC(=O)COC(=O)C)=CC=C2N=CN1CC1=CC=C(F)C(F)=C1 WFPYLTJBIPXIMX-UHFFFAOYSA-N 0.000 claims description 3
• UTWFKZFGFBWHOZ-UHFFFAOYSA-N [2-[[3-[(3,4-dimethylphenyl)methyl]-4-oxoquinazolin-6-yl]amino]-2-oxoethyl] acetate Chemical compound O=C1C2=CC(NC(=O)COC(=O)C)=CC=C2N=CN1CC1=CC=C(C)C(C)=C1 UTWFKZFGFBWHOZ-UHFFFAOYSA-N 0.000 claims description 3
• BNEZMTZHTOUGNZ-UHFFFAOYSA-N [2-[[3-[(4-chlorophenyl)methyl]-4-oxoquinazolin-6-yl]amino]-2-oxoethyl] acetate Chemical compound O=C1C2=CC(NC(=O)COC(=O)C)=CC=C2N=CN1CC1=CC=C(Cl)C=C1 BNEZMTZHTOUGNZ-UHFFFAOYSA-N 0.000 claims description 3
• CKANCWVLJIOYEH-UHFFFAOYSA-N [2-[[3-[1-(3,4-dichlorophenyl)propyl]-4-oxoquinazolin-6-yl]amino]-2-oxoethyl] acetate Chemical compound C1=NC2=CC=C(NC(=O)COC(C)=O)C=C2C(=O)N1C(CC)C1=CC=C(Cl)C(Cl)=C1 CKANCWVLJIOYEH-UHFFFAOYSA-N 0.000 claims description 3
• HZDYPOREEKDJJF-UHFFFAOYSA-N [2-[[3-[3-(2-fluorophenoxy)propyl]-4-oxoquinazolin-6-yl]amino]-2-oxoethyl] acetate Chemical compound O=C1C2=CC(NC(=O)COC(=O)C)=CC=C2N=CN1CCCOC1=CC=CC=C1F HZDYPOREEKDJJF-UHFFFAOYSA-N 0.000 claims description 3
• GXLVMWAYEGFSIW-UHFFFAOYSA-N [2-[[3-[[4-chloro-3-(trifluoromethyl)phenyl]methyl]-4-oxoquinazolin-6-yl]amino]-2-oxoethyl] acetate Chemical compound O=C1C2=CC(NC(=O)COC(=O)C)=CC=C2N=CN1CC1=CC=C(Cl)C(C(F)(F)F)=C1 GXLVMWAYEGFSIW-UHFFFAOYSA-N 0.000 claims description 3
• ABTKFZJCNLNRCZ-UHFFFAOYSA-N [2-[[3-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-4-oxoquinazolin-6-yl]amino]-2-oxoethyl] acetate Chemical compound O=C1C2=CC(NC(=O)COC(=O)C)=CC=C2N=CN1CC1=CC=C(F)C(C(F)(F)F)=C1 ABTKFZJCNLNRCZ-UHFFFAOYSA-N 0.000 claims description 3
• ICZJIWGFLVKEOG-UHFFFAOYSA-N [2-oxo-2-[[4-oxo-3-(3-phenylpropyl)quinazolin-6-yl]amino]ethyl] acetate Chemical compound O=C1C2=CC(NC(=O)COC(=O)C)=CC=C2N=CN1CCCC1=CC=CC=C1 ICZJIWGFLVKEOG-UHFFFAOYSA-N 0.000 claims description 3
• FMNHVMYFGJNUNV-UHFFFAOYSA-N [2-oxo-2-[[4-oxo-3-[[2-(trifluoromethyl)phenyl]methyl]quinazolin-6-yl]amino]ethyl] acetate Chemical compound O=C1C2=CC(NC(=O)COC(=O)C)=CC=C2N=CN1CC1=CC=CC=C1C(F)(F)F FMNHVMYFGJNUNV-UHFFFAOYSA-N 0.000 claims description 3
• ZWNQCQYKCIGXPF-SNAWJCMRSA-N benzyl N-[3-[(E)-4-(2,5-dichlorophenoxy)but-2-enyl]-4-oxoquinazolin-6-yl]carbamate Chemical compound ClC1=CC=C(Cl)C(OC\C=C\CN2C(C3=CC(NC(=O)OCC=4C=CC=CC=4)=CC=C3N=C2)=O)=C1 ZWNQCQYKCIGXPF-SNAWJCMRSA-N 0.000 claims description 3
• CTUJXHSXIAJYII-UHFFFAOYSA-N benzyl n-[3-(naphthalen-2-ylmethyl)-4-oxoquinazolin-6-yl]carbamate Chemical compound C=1C=C2N=CN(CC=3C=C4C=CC=CC4=CC=3)C(=O)C2=CC=1NC(=O)OCC1=CC=CC=C1 CTUJXHSXIAJYII-UHFFFAOYSA-N 0.000 claims description 3
• BMFOQJHODDTXBF-UHFFFAOYSA-N benzyl n-[3-[(3,4-dichlorophenyl)methyl]-2-methyl-4-oxoquinazolin-7-yl]carbamate Chemical compound C=1C=C2C(=O)N(CC=3C=C(Cl)C(Cl)=CC=3)C(C)=NC2=CC=1NC(=O)OCC1=CC=CC=C1 BMFOQJHODDTXBF-UHFFFAOYSA-N 0.000 claims description 3
• HFTPWWWEDCJNRU-UHFFFAOYSA-N benzyl n-[3-[(3,4-dimethylphenyl)methyl]-4-oxoquinazolin-6-yl]carbamate Chemical compound C1=C(C)C(C)=CC=C1CN1C(=O)C2=CC(NC(=O)OCC=3C=CC=CC=3)=CC=C2N=C1 HFTPWWWEDCJNRU-UHFFFAOYSA-N 0.000 claims description 3
• QRFSRYLIFCVTFQ-UHFFFAOYSA-N benzyl n-[3-[(3-methoxyphenyl)methyl]-4-oxoquinazolin-6-yl]carbamate Chemical compound COC1=CC=CC(CN2C(C3=CC(NC(=O)OCC=4C=CC=CC=4)=CC=C3N=C2)=O)=C1 QRFSRYLIFCVTFQ-UHFFFAOYSA-N 0.000 claims description 3
• NBYHWIXZXMOEEL-UHFFFAOYSA-N benzyl n-[3-[1-(3,4-dichlorophenyl)propyl]-4-oxoquinazolin-6-yl]carbamate Chemical compound C1=NC2=CC=C(NC(=O)OCC=3C=CC=CC=3)C=C2C(=O)N1C(CC)C1=CC=C(Cl)C(Cl)=C1 NBYHWIXZXMOEEL-UHFFFAOYSA-N 0.000 claims description 3
• LLUTVUDHDVDAOY-UHFFFAOYSA-N benzyl n-[3-[2-(2-chlorophenoxy)ethyl]-4-oxoquinazolin-6-yl]carbamate Chemical compound ClC1=CC=CC=C1OCCN1C(=O)C2=CC(NC(=O)OCC=3C=CC=CC=3)=CC=C2N=C1 LLUTVUDHDVDAOY-UHFFFAOYSA-N 0.000 claims description 3
• MJJLLTSJHOQRNF-UHFFFAOYSA-N benzyl n-[3-[3-(2,5-dichlorophenoxy)propyl]-4-oxoquinazolin-6-yl]carbamate Chemical compound ClC1=CC=C(Cl)C(OCCCN2C(C3=CC(NC(=O)OCC=4C=CC=CC=4)=CC=C3N=C2)=O)=C1 MJJLLTSJHOQRNF-UHFFFAOYSA-N 0.000 claims description 3
• FUMDPIDLTCAXBG-UHFFFAOYSA-N benzyl n-[3-[3-(2,5-dichlorophenoxy)propyl]-4-oxoquinazolin-7-yl]carbamate Chemical compound ClC1=CC=C(Cl)C(OCCCN2C(C3=CC=C(NC(=O)OCC=4C=CC=CC=4)C=C3N=C2)=O)=C1 FUMDPIDLTCAXBG-UHFFFAOYSA-N 0.000 claims description 3
• GPGOYELTXDBALG-UHFFFAOYSA-N benzyl n-[3-[3-(2-chlorophenoxy)propyl]-4-oxoquinazolin-6-yl]carbamate Chemical compound ClC1=CC=CC=C1OCCCN1C(=O)C2=CC(NC(=O)OCC=3C=CC=CC=3)=CC=C2N=C1 GPGOYELTXDBALG-UHFFFAOYSA-N 0.000 claims description 3
• PLIQHENHLVWGDF-UHFFFAOYSA-N benzyl n-[3-[3-(2-cyanophenoxy)propyl]-4-oxoquinazolin-6-yl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NC(C=C1C2=O)=CC=C1N=CN2CCCOC1=CC=CC=C1C#N PLIQHENHLVWGDF-UHFFFAOYSA-N 0.000 claims description 3
• VSTIRTAQKJYNEU-UHFFFAOYSA-N benzyl n-[3-[3-(2-fluorophenoxy)propyl]-4-oxoquinazolin-6-yl]carbamate Chemical compound FC1=CC=CC=C1OCCCN1C(=O)C2=CC(NC(=O)OCC=3C=CC=CC=3)=CC=C2N=C1 VSTIRTAQKJYNEU-UHFFFAOYSA-N 0.000 claims description 3
• BOEPPJCFWCTYSX-UHFFFAOYSA-N benzyl n-[3-[3-(2-methylphenoxy)propyl]-4-oxoquinazolin-6-yl]carbamate Chemical compound CC1=CC=CC=C1OCCCN1C(=O)C2=CC(NC(=O)OCC=3C=CC=CC=3)=CC=C2N=C1 BOEPPJCFWCTYSX-UHFFFAOYSA-N 0.000 claims description 3
• CCIWOWHZPRYXOZ-UHFFFAOYSA-N benzyl n-[3-[4-(2,5-dichlorophenoxy)butyl]-4-oxoquinazolin-6-yl]carbamate Chemical compound ClC1=CC=C(Cl)C(OCCCCN2C(C3=CC(NC(=O)OCC=4C=CC=CC=4)=CC=C3N=C2)=O)=C1 CCIWOWHZPRYXOZ-UHFFFAOYSA-N 0.000 claims description 3
• KUUODPDZRYGRLM-UHFFFAOYSA-N benzyl n-[3-[[3-[(2,5-dichlorophenoxy)methyl]phenyl]methyl]-4-oxoquinazolin-6-yl]carbamate Chemical compound ClC1=CC=C(Cl)C(OCC=2C=C(CN3C(C4=CC(NC(=O)OCC=5C=CC=CC=5)=CC=C4N=C3)=O)C=CC=2)=C1 KUUODPDZRYGRLM-UHFFFAOYSA-N 0.000 claims description 3
• OMLSHDULJUEBDA-UHFFFAOYSA-N benzyl n-[3-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-4-oxoquinazolin-6-yl]carbamate Chemical compound C1=C(C(F)(F)F)C(F)=CC=C1CN1C(=O)C2=CC(NC(=O)OCC=3C=CC=CC=3)=CC=C2N=C1 OMLSHDULJUEBDA-UHFFFAOYSA-N 0.000 claims description 3
• MYOUMZOICPUQKY-UHFFFAOYSA-N benzyl n-[4-oxo-3-[3-[2-(trifluoromethyl)phenoxy]propyl]quinazolin-6-yl]carbamate Chemical compound FC(F)(F)C1=CC=CC=C1OCCCN1C(=O)C2=CC(NC(=O)OCC=3C=CC=CC=3)=CC=C2N=C1 MYOUMZOICPUQKY-UHFFFAOYSA-N 0.000 claims description 3
• HKTYPJGCHPMZPH-UHFFFAOYSA-N benzyl n-[4-oxo-3-[[3-(trifluoromethyl)phenyl]methyl]quinazolin-6-yl]carbamate Chemical compound FC(F)(F)C1=CC=CC(CN2C(C3=CC(NC(=O)OCC=4C=CC=CC=4)=CC=C3N=C2)=O)=C1 HKTYPJGCHPMZPH-UHFFFAOYSA-N 0.000 claims description 3
• 208000026106 cerebrovascular disease Diseases 0.000 claims description 3
• 208000029078 coronary artery disease Diseases 0.000 claims description 3
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 3
• 208000019622 heart disease Diseases 0.000 claims description 3
• 230000000302 ischemic effect Effects 0.000 claims description 3
• 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 claims description 3
• MUDQUAACYLOZDQ-UHFFFAOYSA-N n,3-bis[(3,4-dichlorophenyl)methyl]-4-oxoquinazoline-7-carboxamide Chemical compound C1=C(Cl)C(Cl)=CC=C1CNC(=O)C1=CC=C2C(=O)N(CC=3C=C(Cl)C(Cl)=CC=3)C=NC2=C1 MUDQUAACYLOZDQ-UHFFFAOYSA-N 0.000 claims description 3
• PFEILJQMMDVRRY-UHFFFAOYSA-N n-[2-[6-[(2-hydroxyacetyl)amino]-4-oxoquinazolin-3-yl]ethyl]-2-(trifluoromethyl)benzamide Chemical compound O=C1C2=CC(NC(=O)CO)=CC=C2N=CN1CCNC(=O)C1=CC=CC=C1C(F)(F)F PFEILJQMMDVRRY-UHFFFAOYSA-N 0.000 claims description 3
• UXWAENYXNXUWHG-JTQLQIEISA-N n-[3-[(1s)-1-[4-chloro-3-(trifluoromethyl)phenyl]ethyl]-4-oxoquinazolin-6-yl]-2-hydroxyacetamide Chemical compound C1([C@H](C)N2C(C3=CC(NC(=O)CO)=CC=C3N=C2)=O)=CC=C(Cl)C(C(F)(F)F)=C1 UXWAENYXNXUWHG-JTQLQIEISA-N 0.000 claims description 3
• VVRLSWLEUJOYBP-UHFFFAOYSA-N n-[3-[(3,4-dichlorophenyl)methyl]-4-oxoquinazolin-6-yl]-2,3-dihydroxypropanamide Chemical compound O=C1C2=CC(NC(=O)C(O)CO)=CC=C2N=CN1CC1=CC=C(Cl)C(Cl)=C1 VVRLSWLEUJOYBP-UHFFFAOYSA-N 0.000 claims description 3
• DYOAUWNBCUNZFI-UHFFFAOYSA-N n-[3-[(3,4-dichlorophenyl)methyl]-4-oxoquinazolin-6-yl]-3-hydroxypropanamide Chemical compound O=C1C2=CC(NC(=O)CCO)=CC=C2N=CN1CC1=CC=C(Cl)C(Cl)=C1 DYOAUWNBCUNZFI-UHFFFAOYSA-N 0.000 claims description 3
• KVSFSNDBMMMPDQ-UHFFFAOYSA-N n-[3-[(3-chlorophenyl)methyl]-4-oxoquinazolin-6-yl]-2-hydroxyacetamide Chemical compound O=C1C2=CC(NC(=O)CO)=CC=C2N=CN1CC1=CC=CC(Cl)=C1 KVSFSNDBMMMPDQ-UHFFFAOYSA-N 0.000 claims description 3
• VVTGCFSFGWYQTR-UHFFFAOYSA-N n-[3-[(4-chlorophenyl)methyl]-4-oxoquinazolin-6-yl]-2-phenoxyacetamide Chemical compound C1=CC(Cl)=CC=C1CN1C(=O)C2=CC(NC(=O)COC=3C=CC=CC=3)=CC=C2N=C1 VVTGCFSFGWYQTR-UHFFFAOYSA-N 0.000 claims description 3
• JMSDMPBPEGROHI-UHFFFAOYSA-N n-[3-[1-(3,4-dichlorophenyl)ethyl]-4-oxoquinazolin-7-yl]-2-hydroxyacetamide Chemical compound C1=NC2=CC(NC(=O)CO)=CC=C2C(=O)N1C(C)C1=CC=C(Cl)C(Cl)=C1 JMSDMPBPEGROHI-UHFFFAOYSA-N 0.000 claims description 3
• HVLUAITXWPRSSM-UHFFFAOYSA-N n-benzyl-3-[(3,4-dichlorophenyl)methyl]-4-oxoquinazoline-7-carboxamide Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1C(=O)C2=CC=C(C(=O)NCC=3C=CC=CC=3)C=C2N=C1 HVLUAITXWPRSSM-UHFFFAOYSA-N 0.000 claims description 3
• 239000000651 prodrug Substances 0.000 claims description 3
• 229940002612 prodrug Drugs 0.000 claims description 3
• 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 2
• PXTCGDTXZZQQLR-UHFFFAOYSA-N 3-[(3,4-dichlorophenyl)methyl]-4-oxoquinazoline-7-carboxamide Chemical compound C=1C(C(=O)N)=CC=C(C2=O)C=1N=CN2CC1=CC=C(Cl)C(Cl)=C1 PXTCGDTXZZQQLR-UHFFFAOYSA-N 0.000 claims description 2
• QNTSLBNOEPZBQR-UHFFFAOYSA-N 3-[(3,4-dichlorophenyl)methyl]-n-(2-hydroxyethyl)-4-oxoquinazoline-6-carboxamide Chemical compound O=C1C2=CC(C(=O)NCCO)=CC=C2N=CN1CC1=CC=C(Cl)C(Cl)=C1 QNTSLBNOEPZBQR-UHFFFAOYSA-N 0.000 claims description 2
• ZTHOZRWAOVJGQG-UHFFFAOYSA-N 3-[(3,4-dichlorophenyl)methyl]-n-(2-hydroxyethyl)-4-oxoquinazoline-7-carboxamide Chemical compound C=1C(C(=O)NCCO)=CC=C(C2=O)C=1N=CN2CC1=CC=C(Cl)C(Cl)=C1 ZTHOZRWAOVJGQG-UHFFFAOYSA-N 0.000 claims description 2
• CAZKMGVRHZMRHJ-UHFFFAOYSA-N 3-[(3,4-dichlorophenyl)methyl]-n-(2-methoxyethyl)-4-oxoquinazoline-6-carboxamide Chemical compound O=C1C2=CC(C(=O)NCCOC)=CC=C2N=CN1CC1=CC=C(Cl)C(Cl)=C1 CAZKMGVRHZMRHJ-UHFFFAOYSA-N 0.000 claims description 2
• QJXVYKCSFVWRJO-UHFFFAOYSA-N 3-[(3,4-dichlorophenyl)methyl]-n-(3-hydroxypropyl)-4-oxoquinazoline-7-carboxamide Chemical compound C=1C(C(=O)NCCCO)=CC=C(C2=O)C=1N=CN2CC1=CC=C(Cl)C(Cl)=C1 QJXVYKCSFVWRJO-UHFFFAOYSA-N 0.000 claims description 2
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 2
• PJMUWESHQUJWJQ-UHFFFAOYSA-N [2-[[3-[1-(3,4-dichlorophenyl)ethyl]-4-oxoquinazolin-7-yl]amino]-2-oxoethyl] acetate Chemical compound C1=NC2=CC(NC(=O)COC(C)=O)=CC=C2C(=O)N1C(C)C1=CC=C(Cl)C(Cl)=C1 PJMUWESHQUJWJQ-UHFFFAOYSA-N 0.000 claims description 2
• SXHQLLQDYKSKDN-UHFFFAOYSA-N benzyl n-[3-[1-(3,4-dichlorophenyl)ethyl]-4-oxoquinazolin-7-yl]carbamate Chemical compound C1=NC2=CC(NC(=O)OCC=3C=CC=CC=3)=CC=C2C(=O)N1C(C)C1=CC=C(Cl)C(Cl)=C1 SXHQLLQDYKSKDN-UHFFFAOYSA-N 0.000 claims description 2
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
• 125000001475 halogen functional group Chemical group 0.000 claims 13
• 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 10
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
• 125000004043 oxo group Chemical group O=* 0.000 claims 2
• 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 1
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
• 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 1
• 125000005164 aryl thioalkyl group Chemical group 0.000 claims 1
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
• 125000004894 pentylamino group Chemical group C(CCCC)N* 0.000 claims 1
• 239000012453 solvate Substances 0.000 claims 1
• 125000005415 substituted alkoxy group Chemical group 0.000 claims 1
• 230000001404 mediated effect Effects 0.000 abstract description 14
• 150000002632 lipids Chemical class 0.000 abstract description 13
• 208000001145 Metabolic Syndrome Diseases 0.000 abstract description 10
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract description 9
• 208000024172 Cardiovascular disease Diseases 0.000 abstract description 6
• 102000004190 Enzymes Human genes 0.000 abstract description 5
• 108090000790 Enzymes Proteins 0.000 abstract description 5
• 230000002159 abnormal effect Effects 0.000 abstract description 3
• 238000002360 preparation method Methods 0.000 description 75
• 239000000203 mixture Substances 0.000 description 56
• 238000006243 chemical reaction Methods 0.000 description 54
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 47
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
• 239000000243 solution Substances 0.000 description 42
• 229910052736 halogen Inorganic materials 0.000 description 30
• 150000002367 halogens Chemical class 0.000 description 30
• 150000001412 amines Chemical class 0.000 description 29
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 23
• 125000004181 carboxyalkyl group Chemical group 0.000 description 22
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 21
• 125000004093 cyano group Chemical group *C#N 0.000 description 21
• 230000000694 effects Effects 0.000 description 21
• 239000002904 solvent Substances 0.000 description 21
• 239000000047 product Substances 0.000 description 20
• 239000011541 reaction mixture Substances 0.000 description 20
• 125000001309 chloro group Chemical group Cl* 0.000 description 19
• 125000004432 carbon atom Chemical group C* 0.000 description 18
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 17
• 125000000392 cycloalkenyl group Chemical group 0.000 description 17
• 235000014113 dietary fatty acids Nutrition 0.000 description 16
• 239000000194 fatty acid Substances 0.000 description 16
• 229930195729 fatty acid Natural products 0.000 description 16
• 238000003786 synthesis reaction Methods 0.000 description 16
• PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 16
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 15
• 208000035475 disorder Diseases 0.000 description 15
• TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical group Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 15
• 150000004665 fatty acids Chemical class 0.000 description 14
• 125000005843 halogen group Chemical group 0.000 description 14
• 230000015572 biosynthetic process Effects 0.000 description 13
• 239000007787 solid Substances 0.000 description 13
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 12
• 241001465754 Metazoa Species 0.000 description 11
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
• 239000002253 acid Substances 0.000 description 11
• 238000003556 assay Methods 0.000 description 11
• 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 11
• 229910052757 nitrogen Inorganic materials 0.000 description 11
• 229910000029 sodium carbonate Inorganic materials 0.000 description 11
• 235000017550 sodium carbonate Nutrition 0.000 description 11
• 238000011282 treatment Methods 0.000 description 11
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
• 125000004414 alkyl thio group Chemical group 0.000 description 10
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
• 229910052938 sodium sulfate Inorganic materials 0.000 description 10
• 235000011152 sodium sulphate Nutrition 0.000 description 10
• 238000012360 testing method Methods 0.000 description 10
• UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 10
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
• 229930194542 Keto Natural products 0.000 description 9
• 239000007832 Na2SO4 Substances 0.000 description 9
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
• 125000002252 acyl group Chemical group 0.000 description 9
• 125000005110 aryl thio group Chemical group 0.000 description 9
• 125000000468 ketone group Chemical group 0.000 description 9
• 239000000725 suspension Substances 0.000 description 9
• 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 9
• 150000003573 thiols Chemical class 0.000 description 9
• JZAIFTGBCQQODC-UHFFFAOYSA-N 6-amino-3-[(3,4-dichlorophenyl)methyl]quinazolin-4-one Chemical compound O=C1C2=CC(N)=CC=C2N=CN1CC1=CC=C(Cl)C(Cl)=C1 JZAIFTGBCQQODC-UHFFFAOYSA-N 0.000 description 8
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
• 239000004480 active ingredient Substances 0.000 description 8
• 125000000033 alkoxyamino group Chemical group 0.000 description 8
• 125000006598 aminocarbonylamino group Chemical group 0.000 description 8
• 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 8
• 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 8
• 125000005368 heteroarylthio group Chemical group 0.000 description 8
• 125000004470 heterocyclooxy group Chemical group 0.000 description 8
• 125000004468 heterocyclylthio group Chemical group 0.000 description 8
• 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 8
• 239000012074 organic phase Substances 0.000 description 8
• 150000003141 primary amines Chemical class 0.000 description 8
• BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 7
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 7
• 241000700159 Rattus Species 0.000 description 7
• 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 7
• 125000004429 atom Chemical group 0.000 description 7
• 210000004185 liver Anatomy 0.000 description 7
• 210000001589 microsome Anatomy 0.000 description 7
• 238000005897 peptide coupling reaction Methods 0.000 description 7
• 210000001519 tissue Anatomy 0.000 description 7
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 7
• LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 6
• WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
• 241000699670 Mus sp. Species 0.000 description 6
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
• 108010062497 VLDL Lipoproteins Proteins 0.000 description 6
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
• 239000011324 bead Substances 0.000 description 6
• 239000003814 drug Substances 0.000 description 6
• 235000019439 ethyl acetate Nutrition 0.000 description 6
• 150000002430 hydrocarbons Chemical group 0.000 description 6
• 239000000463 material Substances 0.000 description 6
• 229910052760 oxygen Inorganic materials 0.000 description 6
• 239000001301 oxygen Substances 0.000 description 6
• 239000000546 pharmaceutical excipient Substances 0.000 description 6
• 239000007858 starting material Substances 0.000 description 6
• SIARJEKBADXQJG-LFZQUHGESA-N stearoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCCCCCCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 SIARJEKBADXQJG-LFZQUHGESA-N 0.000 description 6
• 239000006228 supernatant Substances 0.000 description 6
• IXHNFOOSLAWRBQ-UHFFFAOYSA-N (3,4-dichlorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C(Cl)=C1 IXHNFOOSLAWRBQ-UHFFFAOYSA-N 0.000 description 5
• OQKLSLWVNUUQFG-UHFFFAOYSA-N 3-[(3,4-dichlorophenyl)methyl]-6-nitroquinazolin-4-one Chemical compound O=C1C2=CC([N+](=O)[O-])=CC=C2N=CN1CC1=CC=C(Cl)C(Cl)=C1 OQKLSLWVNUUQFG-UHFFFAOYSA-N 0.000 description 5
• 101150041968 CDC13 gene Proteins 0.000 description 5
• 206010019708 Hepatic steatosis Diseases 0.000 description 5
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 5
• 150000001414 amino alcohols Chemical class 0.000 description 5
• 239000007864 aqueous solution Substances 0.000 description 5
• 239000012131 assay buffer Substances 0.000 description 5
• 238000009472 formulation Methods 0.000 description 5
• 208000006575 hypertriglyceridemia Diseases 0.000 description 5
• RWZYAGGXGHYGMB-UHFFFAOYSA-N o-aminobenzenecarboxylic acid Natural products NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 5
• 239000003960 organic solvent Substances 0.000 description 5
• 229930195734 saturated hydrocarbon Natural products 0.000 description 5
• 125000005017 substituted alkenyl group Chemical group 0.000 description 5
• 239000003826 tablet Substances 0.000 description 5
• 229940124597 therapeutic agent Drugs 0.000 description 5
• GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 5
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
• FBHFAVIJCDLHQF-UHFFFAOYSA-N 2-amino-4-(2-methoxyethylcarbamoyl)benzoic acid Chemical compound COCCNC(=O)C1=CC=C(C(O)=O)C(N)=C1 FBHFAVIJCDLHQF-UHFFFAOYSA-N 0.000 description 4
• ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 4
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
• KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 4
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
• NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 4
• 229910000564 Raney nickel Inorganic materials 0.000 description 4
• PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
• 239000007983 Tris buffer Substances 0.000 description 4
• HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 4
• PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
• 239000003795 chemical substances by application Substances 0.000 description 4
• 235000012000 cholesterol Nutrition 0.000 description 4
• 230000007812 deficiency Effects 0.000 description 4
• 238000001035 drying Methods 0.000 description 4
• 230000002440 hepatic effect Effects 0.000 description 4
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
• 238000001727 in vivo Methods 0.000 description 4
• 230000005764 inhibitory process Effects 0.000 description 4
• 239000010410 layer Substances 0.000 description 4
• QJEFWSPIFLLUIB-UHFFFAOYSA-N methyl 2-amino-4-(2-methoxyethylcarbamoyl)benzoate Chemical compound COCCNC(=O)C1=CC=C(C(=O)OC)C(N)=C1 QJEFWSPIFLLUIB-UHFFFAOYSA-N 0.000 description 4
• 230000003228 microsomal effect Effects 0.000 description 4
• BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 4
• 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
• 239000012044 organic layer Substances 0.000 description 4
• 239000008188 pellet Substances 0.000 description 4
• 239000006187 pill Substances 0.000 description 4
• 239000002798 polar solvent Substances 0.000 description 4
• 238000000746 purification Methods 0.000 description 4
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
• 230000002829 reductive effect Effects 0.000 description 4
• 238000003756 stirring Methods 0.000 description 4
• 239000000758 substrate Substances 0.000 description 4
• 229910052717 sulfur Inorganic materials 0.000 description 4
• 239000011593 sulfur Substances 0.000 description 4
• 208000024891 symptom Diseases 0.000 description 4
• 150000003626 triacylglycerols Chemical class 0.000 description 4
• YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 4
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 4
• VRVUKQWNRPNACD-UHFFFAOYSA-N 1-isocyanatopentane Chemical compound CCCCCN=C=O VRVUKQWNRPNACD-UHFFFAOYSA-N 0.000 description 3
• CAQJCULNKULRGE-UHFFFAOYSA-N 2-amino-n-[(3,4-dichlorophenyl)methyl]-5-nitrobenzamide Chemical compound NC1=CC=C([N+]([O-])=O)C=C1C(=O)NCC1=CC=C(Cl)C(Cl)=C1 CAQJCULNKULRGE-UHFFFAOYSA-N 0.000 description 3
• KWFCSMSCNOVLBA-UHFFFAOYSA-N 2-hydroxy-3-oxobutanoic acid Chemical compound CC(=O)C(O)C(O)=O KWFCSMSCNOVLBA-UHFFFAOYSA-N 0.000 description 3
• RUCHWTKMOWXHLU-UHFFFAOYSA-N 5-nitroanthranilic acid Chemical compound NC1=CC=C([N+]([O-])=O)C=C1C(O)=O RUCHWTKMOWXHLU-UHFFFAOYSA-N 0.000 description 3
• HLSPPVABILCCRE-UHFFFAOYSA-N 6-amino-3-[(3,4-dichlorophenyl)methyl]pyrido[2,3-d]pyrimidin-4-one Chemical compound O=C1C2=CC(N)=CN=C2N=CN1CC1=CC=C(Cl)C(Cl)=C1 HLSPPVABILCCRE-UHFFFAOYSA-N 0.000 description 3
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 3
• 229940123980 Desaturase inhibitor Drugs 0.000 description 3
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
• WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 3
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
• FSZQIWNVQNRBBK-UHFFFAOYSA-N [2-[[3-[(3,4-dichlorophenyl)methyl]-4-oxopyrido[2,3-d]pyrimidin-6-yl]amino]-2-oxoethyl] acetate Chemical compound O=C1C2=CC(NC(=O)COC(=O)C)=CN=C2N=CN1CC1=CC=C(Cl)C(Cl)=C1 FSZQIWNVQNRBBK-UHFFFAOYSA-N 0.000 description 3
• 125000003710 aryl alkyl group Chemical group 0.000 description 3
• XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
• 230000004071 biological effect Effects 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 125000002837 carbocyclic group Chemical group 0.000 description 3
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
• 238000005119 centrifugation Methods 0.000 description 3
• 238000004587 chromatography analysis Methods 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 238000007796 conventional method Methods 0.000 description 3
• 235000005911 diet Nutrition 0.000 description 3
• 230000037213 diet Effects 0.000 description 3
• 239000003085 diluting agent Substances 0.000 description 3
• 208000010706 fatty liver disease Diseases 0.000 description 3
• 125000004475 heteroaralkyl group Chemical group 0.000 description 3
• 125000005842 heteroatom Chemical group 0.000 description 3
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
• 210000001853 liver microsome Anatomy 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• BWEIHRLYAZNBHP-UHFFFAOYSA-N n-[3-[[3-[(2,5-dichlorophenoxy)methyl]phenyl]methyl]-4-oxoquinazolin-6-yl]-2-hydroxyacetamide Chemical compound O=C1C2=CC(NC(=O)CO)=CC=C2N=CN1CC(C=1)=CC=CC=1COC1=CC(Cl)=CC=C1Cl BWEIHRLYAZNBHP-UHFFFAOYSA-N 0.000 description 3
• 238000006396 nitration reaction Methods 0.000 description 3
• 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 3
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 3
• 150000002989 phenols Chemical class 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 239000002244 precipitate Substances 0.000 description 3
• 238000004366 reverse phase liquid chromatography Methods 0.000 description 3
• 238000007363 ring formation reaction Methods 0.000 description 3
• 229920006395 saturated elastomer Polymers 0.000 description 3
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
• 125000005346 substituted cycloalkyl group Chemical group 0.000 description 3
• NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
• QPVAKLYDSSJWAV-UHFFFAOYSA-N 2-amino-1-n-[(3,4-dichlorophenyl)methyl]-4-n-(2-methoxyethyl)benzene-1,4-dicarboxamide Chemical compound NC1=CC(C(=O)NCCOC)=CC=C1C(=O)NCC1=CC=C(Cl)C(Cl)=C1 QPVAKLYDSSJWAV-UHFFFAOYSA-N 0.000 description 2
• YSYROWVWBAZMDS-UHFFFAOYSA-N 2-amino-n-[(3,4-dichlorophenyl)methyl]-5-nitropyridine-3-carboxamide Chemical compound NC1=NC=C([N+]([O-])=O)C=C1C(=O)NCC1=CC=C(Cl)C(Cl)=C1 YSYROWVWBAZMDS-UHFFFAOYSA-N 0.000 description 2
• 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 2
• XFLDRJAYKUZHMR-UHFFFAOYSA-N 2-hydroxy-n-[4-oxo-3-(3-phenoxyphenyl)quinazolin-6-yl]acetamide Chemical compound O=C1C2=CC(NC(=O)CO)=CC=C2N=CN1C(C=1)=CC=CC=1OC1=CC=CC=C1 XFLDRJAYKUZHMR-UHFFFAOYSA-N 0.000 description 2
• VMLHVXZWQQEASW-UHFFFAOYSA-N 3-[(3,4-dichlorophenyl)methyl]-6-methylquinazolin-4-one Chemical compound O=C1C2=CC(C)=CC=C2N=CN1CC1=CC=C(Cl)C(Cl)=C1 VMLHVXZWQQEASW-UHFFFAOYSA-N 0.000 description 2
• WRGHAVXCXGBHQI-UHFFFAOYSA-N 3-[(3,4-dichlorophenyl)methyl]-6-nitropyrido[2,3-d]pyrimidin-4-one Chemical compound O=C1C2=CC([N+](=O)[O-])=CN=C2N=CN1CC1=CC=C(Cl)C(Cl)=C1 WRGHAVXCXGBHQI-UHFFFAOYSA-N 0.000 description 2
• NMAKJOWVEDTHOA-UHFFFAOYSA-N 4-(chloromethyl)-1,3-thiazol-2-amine;hydron;chloride Chemical compound Cl.NC1=NC(CCl)=CS1 NMAKJOWVEDTHOA-UHFFFAOYSA-N 0.000 description 2
• UEALKTCRMBVTFN-UHFFFAOYSA-N 4-nitroanthranilic acid Chemical group NC1=CC([N+]([O-])=O)=CC=C1C(O)=O UEALKTCRMBVTFN-UHFFFAOYSA-N 0.000 description 2
• OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 2
• PXDDCBOOHGDLBL-UHFFFAOYSA-N 5-methyl-1h-quinazolin-4-one Chemical compound N1C=NC(=O)C2=C1C=CC=C2C PXDDCBOOHGDLBL-UHFFFAOYSA-N 0.000 description 2
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
• UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
• BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 2
• 208000004930 Fatty Liver Diseases 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
• 206010019728 Hepatitis alcoholic Diseases 0.000 description 2
• 201000001431 Hyperuricemia Diseases 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
• 208000021642 Muscular disease Diseases 0.000 description 2
• 201000009623 Myopathy Diseases 0.000 description 2
• 101100513046 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) eth-1 gene Proteins 0.000 description 2
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
• PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
• QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
• KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
• LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
• 239000007868 Raney catalyst Substances 0.000 description 2
• 206010039792 Seborrhoea Diseases 0.000 description 2
• PQRKPYLNZGDCFH-UHFFFAOYSA-N Sterculic-saeure Natural products CCCCCCCCC1=C(CCCCCCCC(O)=O)C1 PQRKPYLNZGDCFH-UHFFFAOYSA-N 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 239000012317 TBTU Substances 0.000 description 2
• 239000004164 Wax ester Substances 0.000 description 2
• NGJSPAZQTQWTOI-UHFFFAOYSA-N [2-[[3-[(3,4-dichlorophenyl)methyl]-4-oxoquinazolin-6-yl]amino]-2-oxoethyl] acetate Chemical compound O=C1C2=CC(NC(=O)COC(=O)C)=CC=C2N=CN1CC1=CC=C(Cl)C(Cl)=C1 NGJSPAZQTQWTOI-UHFFFAOYSA-N 0.000 description 2
• CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
• 210000001789 adipocyte Anatomy 0.000 description 2
• 210000000577 adipose tissue Anatomy 0.000 description 2
• 208000002353 alcoholic hepatitis Diseases 0.000 description 2
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
• 125000003277 amino group Chemical group 0.000 description 2
• VIROVYVQCGLCII-UHFFFAOYSA-N amobarbital Chemical compound CC(C)CCC1(CC)C(=O)NC(=O)NC1=O VIROVYVQCGLCII-UHFFFAOYSA-N 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 125000000732 arylene group Chemical group 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 2
• CJXAHOHUCKFMCR-UHFFFAOYSA-N benzyl n-[3-[(3,4-dichlorophenyl)methyl]-4-oxopyrido[2,3-d]pyrimidin-6-yl]carbamate Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1C(=O)C2=CC(NC(=O)OCC=3C=CC=CC=3)=CN=C2N=C1 CJXAHOHUCKFMCR-UHFFFAOYSA-N 0.000 description 2
• WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
• 239000012267 brine Substances 0.000 description 2
• RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
• 150000001720 carbohydrates Chemical class 0.000 description 2
• 235000014633 carbohydrates Nutrition 0.000 description 2
• 229910052799 carbon Inorganic materials 0.000 description 2
• 210000004027 cell Anatomy 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 238000012512 characterization method Methods 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 238000004440 column chromatography Methods 0.000 description 2
• 238000013270 controlled release Methods 0.000 description 2
• 239000007822 coupling agent Substances 0.000 description 2
• 125000004122 cyclic group Chemical group 0.000 description 2
• HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
• 230000003111 delayed effect Effects 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
• 208000037765 diseases and disorders Diseases 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 239000003937 drug carrier Substances 0.000 description 2
• 239000012055 enteric layer Substances 0.000 description 2
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
• 238000000605 extraction Methods 0.000 description 2
• 239000012467 final product Substances 0.000 description 2
• 238000010438 heat treatment Methods 0.000 description 2
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
• 210000003494 hepatocyte Anatomy 0.000 description 2
• BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
• ALBYIUDWACNRRB-UHFFFAOYSA-N hexanamide Chemical compound CCCCCC(N)=O ALBYIUDWACNRRB-UHFFFAOYSA-N 0.000 description 2
• 238000000265 homogenisation Methods 0.000 description 2
• 239000011539 homogenization buffer Substances 0.000 description 2
• IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
• 230000001965 increasing effect Effects 0.000 description 2
• PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
• 239000011261 inert gas Substances 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 150000007529 inorganic bases Chemical class 0.000 description 2
• 238000007689 inspection Methods 0.000 description 2
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
• AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
• 230000037356 lipid metabolism Effects 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 238000004519 manufacturing process Methods 0.000 description 2
• 239000002609 medium Substances 0.000 description 2
• GABFDPIDDONJAL-UHFFFAOYSA-N methyl 2-amino-4-(methylcarbamoyl)benzoate Chemical compound CNC(=O)C1=CC=C(C(=O)OC)C(N)=C1 GABFDPIDDONJAL-UHFFFAOYSA-N 0.000 description 2
• NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical class [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 2
• 150000007522 mineralic acids Chemical class 0.000 description 2
• 235000021281 monounsaturated fatty acids Nutrition 0.000 description 2
• 210000004400 mucous membrane Anatomy 0.000 description 2
• 210000003205 muscle Anatomy 0.000 description 2
• SYRGPVPKQWDULB-UHFFFAOYSA-N n-[3-[(3,4-dichlorophenyl)methyl]-4-oxopyrido[2,3-d]pyrimidin-6-yl]-2-hydroxyacetamide Chemical compound O=C1C2=CC(NC(=O)CO)=CN=C2N=CN1CC1=CC=C(Cl)C(Cl)=C1 SYRGPVPKQWDULB-UHFFFAOYSA-N 0.000 description 2
• ZFEWLTXJQNEROX-UHFFFAOYSA-N n-[3-[(3,4-difluorophenyl)methyl]-4-oxoquinazolin-6-yl]acetamide Chemical compound O=C1C2=CC(NC(=O)C)=CC=C2N=CN1CC1=CC=C(F)C(F)=C1 ZFEWLTXJQNEROX-UHFFFAOYSA-N 0.000 description 2
• RVZNBCNIQICCAZ-UHFFFAOYSA-N n-[3-[(4-chlorophenyl)methyl]-4-oxopyrido[2,3-d]pyrimidin-6-yl]-2-hydroxyacetamide Chemical compound O=C1C2=CC(NC(=O)CO)=CN=C2N=CN1CC1=CC=C(Cl)C=C1 RVZNBCNIQICCAZ-UHFFFAOYSA-N 0.000 description 2
• VZNPPOBCICILCV-UHFFFAOYSA-N n-[4-oxo-3-[[4-(trifluoromethyl)phenyl]methyl]quinazolin-6-yl]acetamide Chemical compound O=C1C2=CC(NC(=O)C)=CC=C2N=CN1CC1=CC=C(C(F)(F)F)C=C1 VZNPPOBCICILCV-UHFFFAOYSA-N 0.000 description 2
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 125000001624 naphthyl group Chemical group 0.000 description 2
• 150000002828 nitro derivatives Chemical class 0.000 description 2
• 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 2
• 230000037312 oily skin Effects 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 235000005985 organic acids Nutrition 0.000 description 2
• 150000007530 organic bases Chemical class 0.000 description 2
• 150000002943 palmitic acids Chemical class 0.000 description 2
• 238000007911 parenteral administration Methods 0.000 description 2
• 230000010412 perfusion Effects 0.000 description 2
• 239000008177 pharmaceutical agent Substances 0.000 description 2
• 238000005191 phase separation Methods 0.000 description 2
• RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
• 150000003904 phospholipids Chemical class 0.000 description 2
• 229920000642 polymer Polymers 0.000 description 2
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
• JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 2
• 150000003254 radicals Chemical group 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• 230000028327 secretion Effects 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• 235000017557 sodium bicarbonate Nutrition 0.000 description 2
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
• 239000008247 solid mixture Substances 0.000 description 2
• 231100000240 steatosis hepatitis Toxicity 0.000 description 2
• 239000011550 stock solution Substances 0.000 description 2
• 210000002784 stomach Anatomy 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• 125000005156 substituted alkylene group Chemical group 0.000 description 2
• 125000004426 substituted alkynyl group Chemical group 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 150000003457 sulfones Chemical class 0.000 description 2
• 150000003462 sulfoxides Chemical class 0.000 description 2
• 238000010189 synthetic method Methods 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
• 201000005665 thrombophilia Diseases 0.000 description 2
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 238000012384 transportation and delivery Methods 0.000 description 2
• GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
• 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
• 229920002554 vinyl polymer Polymers 0.000 description 2
• 235000019386 wax ester Nutrition 0.000 description 2
• 238000010626 work up procedure Methods 0.000 description 2
• QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
• YMVFJGSXZNNUDW-UHFFFAOYSA-N (4-chlorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C=C1 YMVFJGSXZNNUDW-UHFFFAOYSA-N 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
• WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
• SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
• BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 description 1
• YGTAZGSLCXNBQL-UHFFFAOYSA-N 1,2,4-thiadiazole Chemical compound C=1N=CSN=1 YGTAZGSLCXNBQL-UHFFFAOYSA-N 0.000 description 1
• FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical compound C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 description 1
• MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical compound C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 description 1
• ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
• JGDCGJQIVCLGMJ-UHFFFAOYSA-N 1-[3-[(3,4-dichlorophenyl)methyl]-4-oxoquinazolin-6-yl]-3-pentylurea Chemical compound O=C1C2=CC(NC(=O)NCCCCC)=CC=C2N=CN1CC1=CC=C(Cl)C(Cl)=C1 JGDCGJQIVCLGMJ-UHFFFAOYSA-N 0.000 description 1
• GQNHARINTUWVGG-UHFFFAOYSA-N 1-ethoxy-2-(2-ethoxyethoxy)ethane Chemical compound [CH2]COCCOCCOCC GQNHARINTUWVGG-UHFFFAOYSA-N 0.000 description 1
• PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
• WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
• TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
• BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
• XKEBMWRWBWRQAO-UHFFFAOYSA-N 1h-pyrido[2,3-d]pyrimidin-4-one Chemical group C1=CC=C2C(=O)N=CNC2=N1 XKEBMWRWBWRQAO-UHFFFAOYSA-N 0.000 description 1
• ZABMHLDQFJHDSC-UHFFFAOYSA-N 2,3-dihydro-1,3-oxazole Chemical compound C1NC=CO1 ZABMHLDQFJHDSC-UHFFFAOYSA-N 0.000 description 1
• VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
• IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
• MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 1
• PNMMFQMGLADPKZ-UHFFFAOYSA-N 2-amino-1-N-[(3,4-dichlorophenyl)methyl]-4-N-methylbenzene-1,4-dicarboxamide Chemical compound NC1=C(C(=O)NCC2=CC(=C(C=C2)Cl)Cl)C=CC(=C1)C(=O)NC PNMMFQMGLADPKZ-UHFFFAOYSA-N 0.000 description 1
• MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
• IKLJYCLKYVIQDZ-UHFFFAOYSA-N 2-amino-4-(methylcarbamoyl)benzoic acid Chemical compound CNC(=O)C1=CC=C(C(O)=O)C(N)=C1 IKLJYCLKYVIQDZ-UHFFFAOYSA-N 0.000 description 1
• NBUUUJWWOARGNW-UHFFFAOYSA-N 2-amino-5-methylbenzoic acid Chemical compound CC1=CC=C(N)C(C(O)=O)=C1 NBUUUJWWOARGNW-UHFFFAOYSA-N 0.000 description 1
• QZTCYRNALLZQJI-UHFFFAOYSA-N 2-amino-5-nitro-n-[[3-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound NC1=CC=C([N+]([O-])=O)C=C1C(=O)NCC1=CC=CC(C(F)(F)F)=C1 QZTCYRNALLZQJI-UHFFFAOYSA-N 0.000 description 1
• TWKSLPBPZVSJLK-UHFFFAOYSA-N 2-amino-5-nitro-n-[[4-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound NC1=CC=C([N+]([O-])=O)C=C1C(=O)NCC1=CC=C(C(F)(F)F)C=C1 TWKSLPBPZVSJLK-UHFFFAOYSA-N 0.000 description 1
• OVKURXPJUDVKKU-UHFFFAOYSA-N 2-amino-5-nitronicotinic acid Chemical compound NC1=NC=C([N+]([O-])=O)C=C1C(O)=O OVKURXPJUDVKKU-UHFFFAOYSA-N 0.000 description 1
• XHYVBIXKORFHFM-UHFFFAOYSA-N 2-amino-6-methylbenzoic acid Chemical compound CC1=CC=CC(N)=C1C(O)=O XHYVBIXKORFHFM-UHFFFAOYSA-N 0.000 description 1
• PMZAYMMXEALRRC-UHFFFAOYSA-N 2-amino-N-[2-(3,4-dichlorophenyl)ethyl]-5-nitrobenzamide Chemical compound NC1=CC=C([N+]([O-])=O)C=C1C(=O)NCCC1=CC=C(Cl)C(Cl)=C1 PMZAYMMXEALRRC-UHFFFAOYSA-N 0.000 description 1
• DSKBYZTWFRECIU-UHFFFAOYSA-N 2-amino-N-[[4-(1-benzothiophen-5-yl)phenyl]methyl]-5-nitrobenzamide Chemical compound NC1=CC=C([N+]([O-])=O)C=C1C(=O)NCC1=CC=C(C=2C=C3C=CSC3=CC=2)C=C1 DSKBYZTWFRECIU-UHFFFAOYSA-N 0.000 description 1
• XMVOGBLEMPNRQK-UHFFFAOYSA-N 2-amino-N-[[4-(1-benzothiophen-6-yl)phenyl]methyl]-5-nitrobenzamide Chemical compound NC1=CC=C([N+]([O-])=O)C=C1C(=O)NCC1=CC=C(C=2C=C3SC=CC3=CC=2)C=C1 XMVOGBLEMPNRQK-UHFFFAOYSA-N 0.000 description 1
• OBBCMRBQXLRIIU-UHFFFAOYSA-N 2-amino-n-[(3,4-dichlorophenyl)methyl]-4-nitrobenzamide Chemical compound NC1=CC([N+]([O-])=O)=CC=C1C(=O)NCC1=CC=C(Cl)C(Cl)=C1 OBBCMRBQXLRIIU-UHFFFAOYSA-N 0.000 description 1
• UQXWARXDFGAXQC-UHFFFAOYSA-N 2-amino-n-[(3,4-difluorophenyl)methyl]-4-nitrobenzamide Chemical compound NC1=CC([N+]([O-])=O)=CC=C1C(=O)NCC1=CC=C(F)C(F)=C1 UQXWARXDFGAXQC-UHFFFAOYSA-N 0.000 description 1
• TWBNPIFGWXATFS-UHFFFAOYSA-N 2-amino-n-[(3-chloro-4-fluorophenyl)methyl]-5-nitrobenzamide Chemical compound NC1=CC=C([N+]([O-])=O)C=C1C(=O)NCC1=CC=C(F)C(Cl)=C1 TWBNPIFGWXATFS-UHFFFAOYSA-N 0.000 description 1
• MSBUVQAVWMNKER-UHFFFAOYSA-N 2-amino-n-[(3-chlorophenyl)methyl]-4-nitrobenzamide Chemical compound NC1=CC([N+]([O-])=O)=CC=C1C(=O)NCC1=CC=CC(Cl)=C1 MSBUVQAVWMNKER-UHFFFAOYSA-N 0.000 description 1
• LBVHFPVCZSWYCQ-UHFFFAOYSA-N 2-amino-n-[(4-bromophenyl)methyl]-5-nitrobenzamide Chemical compound NC1=CC=C([N+]([O-])=O)C=C1C(=O)NCC1=CC=C(Br)C=C1 LBVHFPVCZSWYCQ-UHFFFAOYSA-N 0.000 description 1
• UGEGVWRFDKPINM-UHFFFAOYSA-N 2-amino-n-[(4-chloro-3-fluorophenyl)methyl]-5-nitrobenzamide Chemical compound NC1=CC=C([N+]([O-])=O)C=C1C(=O)NCC1=CC=C(Cl)C(F)=C1 UGEGVWRFDKPINM-UHFFFAOYSA-N 0.000 description 1
• QNFWENBOWGZOFX-UHFFFAOYSA-N 2-amino-n-[(4-chlorophenyl)methyl]-4-nitrobenzamide Chemical compound NC1=CC([N+]([O-])=O)=CC=C1C(=O)NCC1=CC=C(Cl)C=C1 QNFWENBOWGZOFX-UHFFFAOYSA-N 0.000 description 1
• SFTBQEIYFSDVQN-UHFFFAOYSA-N 2-amino-n-[(4-chlorophenyl)methyl]-5-nitrobenzamide Chemical compound NC1=CC=C([N+]([O-])=O)C=C1C(=O)NCC1=CC=C(Cl)C=C1 SFTBQEIYFSDVQN-UHFFFAOYSA-N 0.000 description 1
• DFTBKYMJVUNZSU-UHFFFAOYSA-N 2-amino-n-[(4-fluorophenyl)methyl]-5-nitrobenzamide Chemical compound NC1=CC=C([N+]([O-])=O)C=C1C(=O)NCC1=CC=C(F)C=C1 DFTBKYMJVUNZSU-UHFFFAOYSA-N 0.000 description 1
• JMTGITJTARHARR-UHFFFAOYSA-N 2-amino-n-[(4-methoxyphenyl)methyl]-5-nitrobenzamide Chemical compound C1=CC(OC)=CC=C1CNC(=O)C1=CC([N+]([O-])=O)=CC=C1N JMTGITJTARHARR-UHFFFAOYSA-N 0.000 description 1
• AUVALWUPUHHNQV-UHFFFAOYSA-N 2-hydroxy-3-propylbenzoic acid Chemical class CCCC1=CC=CC(C(O)=O)=C1O AUVALWUPUHHNQV-UHFFFAOYSA-N 0.000 description 1
• VLRSADZEDXVUPG-UHFFFAOYSA-N 2-naphthalen-1-ylpyridine Chemical compound N1=CC=CC=C1C1=CC=CC2=CC=CC=C12 VLRSADZEDXVUPG-UHFFFAOYSA-N 0.000 description 1
• GUPGZURVZDIQPM-UHFFFAOYSA-N 2-oxoethyl acetate Chemical compound CC(=O)OCC=O GUPGZURVZDIQPM-UHFFFAOYSA-N 0.000 description 1
• AOPRXJXHLWYPQR-UHFFFAOYSA-N 2-phenoxyacetamide Chemical compound NC(=O)COC1=CC=CC=C1 AOPRXJXHLWYPQR-UHFFFAOYSA-N 0.000 description 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
• 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
• FXIFNMDJFOVBSD-UHFFFAOYSA-N 3-[(3,4-dichlorophenyl)methyl]-4-oxoquinazoline-6-carboxylic acid Chemical compound O=C1C2=CC(C(=O)O)=CC=C2N=CN1CC1=CC=C(Cl)C(Cl)=C1 FXIFNMDJFOVBSD-UHFFFAOYSA-N 0.000 description 1
• ONCATNSTLAKARK-UHFFFAOYSA-N 3-[(3,4-dichlorophenyl)methyl]-4-oxoquinazoline-7-carboxylic acid Chemical compound C=1C(C(=O)O)=CC=C(C2=O)C=1N=CN2CC1=CC=C(Cl)C(Cl)=C1 ONCATNSTLAKARK-UHFFFAOYSA-N 0.000 description 1
• QKOKLMFCKLEFDV-UHFFFAOYSA-N 3-amino-4-methoxycarbonylbenzoic acid Chemical compound COC(=O)C1=CC=C(C(O)=O)C=C1N QKOKLMFCKLEFDV-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• AHVBOKXTTGPSGM-UHFFFAOYSA-N 4-oxo-1h-quinazoline-6-carboxamide Chemical class N1=CN=C(O)C2=CC(C(=O)N)=CC=C21 AHVBOKXTTGPSGM-UHFFFAOYSA-N 0.000 description 1
• VHPNTKQQTKCONR-UHFFFAOYSA-N 4-oxo-1h-quinazoline-7-carboxamide Chemical class N1=CNC(=O)C=2C1=CC(C(=O)N)=CC=2 VHPNTKQQTKCONR-UHFFFAOYSA-N 0.000 description 1
• GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• 235000006491 Acacia senegal Nutrition 0.000 description 1
• 244000215068 Acacia senegal Species 0.000 description 1
• 208000002874 Acne Vulgaris Diseases 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 108010071619 Apolipoproteins Proteins 0.000 description 1
• 102000007592 Apolipoproteins Human genes 0.000 description 1
• 102000013918 Apolipoproteins E Human genes 0.000 description 1
• 108010025628 Apolipoproteins E Proteins 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 241000271566 Aves Species 0.000 description 1
• NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical group C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
• 206010006895 Cachexia Diseases 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 208000005623 Carcinogenesis Diseases 0.000 description 1
• 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 description 1
• 102100027943 Carnitine O-palmitoyltransferase 1, liver isoform Human genes 0.000 description 1
• 101710120614 Carnitine O-palmitoyltransferase 1, liver isoform Proteins 0.000 description 1
• 101710108984 Carnitine O-palmitoyltransferase 1, muscle isoform Proteins 0.000 description 1
• 102100024853 Carnitine O-palmitoyltransferase 2, mitochondrial Human genes 0.000 description 1
• 201000002929 Carnitine palmitoyltransferase II deficiency Diseases 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 229920000858 Cyclodextrin Polymers 0.000 description 1
• 201000003883 Cystic fibrosis Diseases 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 201000004624 Dermatitis Diseases 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
• 208000035762 Disorder of lipid metabolism Diseases 0.000 description 1
• 206010072268 Drug-induced liver injury Diseases 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
• 239000005977 Ethylene Substances 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• 201000001376 Familial Combined Hyperlipidemia Diseases 0.000 description 1
• 102000009114 Fatty acid desaturases Human genes 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 208000002705 Glucose Intolerance Diseases 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 description 1
• 206010019668 Hepatic fibrosis Diseases 0.000 description 1
• 208000033981 Hereditary haemochromatosis Diseases 0.000 description 1
• 101100041816 Homo sapiens SCD gene Proteins 0.000 description 1
• 208000001021 Hyperlipoproteinemia Type I Diseases 0.000 description 1
• WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 206010065973 Iron Overload Diseases 0.000 description 1
• LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
• 108010044467 Isoenzymes Proteins 0.000 description 1
• PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
• 206010023330 Keloid scar Diseases 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• 108010007622 LDL Lipoproteins Proteins 0.000 description 1
• 102000007330 LDL Lipoproteins Human genes 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 102000016267 Leptin Human genes 0.000 description 1
• 108010092277 Leptin Proteins 0.000 description 1
• 102000003960 Ligases Human genes 0.000 description 1
• 108090000364 Ligases Proteins 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical class CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• SOWBFZRMHSNYGE-UHFFFAOYSA-N Monoamide-Oxalic acid Natural products NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• 235000009421 Myristica fragrans Nutrition 0.000 description 1
• KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
• UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
• HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
• 150000001204 N-oxides Chemical class 0.000 description 1
• 229910003813 NRa Inorganic materials 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 208000025966 Neurological disease Diseases 0.000 description 1
• 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 206010033307 Overweight Diseases 0.000 description 1
• 235000021314 Palmitic acid Nutrition 0.000 description 1
• 206010033645 Pancreatitis Diseases 0.000 description 1
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 206010036618 Premenstrual syndrome Diseases 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• 241000382353 Pupa Species 0.000 description 1
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
• 101150097713 SCD1 gene Proteins 0.000 description 1
• 101000650578 Salmonella phage P22 Regulatory protein C3 Proteins 0.000 description 1
• 229920001800 Shellac Polymers 0.000 description 1
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
• DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 102100028897 Stearoyl-CoA desaturase Human genes 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 208000026062 Tissue disease Diseases 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 101001040920 Triticum aestivum Alpha-amylase inhibitor 0.28 Proteins 0.000 description 1
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
• DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
• 230000003187 abdominal effect Effects 0.000 description 1
• 201000010390 abdominal obesity-metabolic syndrome 1 Diseases 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 239000003070 absorption delaying agent Substances 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 229940081735 acetylcellulose Drugs 0.000 description 1
• 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 206010000496 acne Diseases 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 150000003973 alkyl amines Chemical class 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 230000001668 ameliorated effect Effects 0.000 description 1
• 125000003368 amide group Chemical group 0.000 description 1
• 208000022531 anorexia Diseases 0.000 description 1
• 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 239000000074 antisense oligonucleotide Substances 0.000 description 1
• 238000012230 antisense oligonucleotides Methods 0.000 description 1
• 239000011260 aqueous acid Substances 0.000 description 1
• 239000003125 aqueous solvent Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 229960003121 arginine Drugs 0.000 description 1
• 150000004982 aromatic amines Chemical class 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• 150000001540 azides Chemical class 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• JGGVHSZLXLMTQE-UHFFFAOYSA-N benzyl n-[3-[(4-chlorophenyl)methyl]-4-oxopyrido[2,3-d]pyrimidin-6-yl]carbamate Chemical compound C1=CC(Cl)=CC=C1CN1C(=O)C2=CC(NC(=O)OCC=3C=CC=CC=3)=CN=C2N=C1 JGGVHSZLXLMTQE-UHFFFAOYSA-N 0.000 description 1
• 238000005574 benzylation reaction Methods 0.000 description 1
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
• MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 229960003237 betaine Drugs 0.000 description 1
• 239000004305 biphenyl Substances 0.000 description 1
• 235000010290 biphenyl Nutrition 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 125000001246 bromo group Chemical group Br* 0.000 description 1
• 239000007975 buffered saline Substances 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 229960001948 caffeine Drugs 0.000 description 1
• VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 239000000378 calcium silicate Substances 0.000 description 1
• 229910052918 calcium silicate Inorganic materials 0.000 description 1
• 229960003340 calcium silicate Drugs 0.000 description 1
• 235000012241 calcium silicate Nutrition 0.000 description 1
• OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
• 230000036952 cancer formation Effects 0.000 description 1
• 235000021024 carbohydrate-rich diet Nutrition 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• 231100000504 carcinogenesis Toxicity 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 229920002301 cellulose acetate Polymers 0.000 description 1
• 229960000541 cetyl alcohol Drugs 0.000 description 1
• FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
• SKCNIGRBPJIUBQ-UHFFFAOYSA-N chloroform;ethyl acetate Chemical compound ClC(Cl)Cl.CCOC(C)=O SKCNIGRBPJIUBQ-UHFFFAOYSA-N 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• 235000013985 cinnamic acid Nutrition 0.000 description 1
• 229930016911 cinnamic acid Natural products 0.000 description 1
• WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
• 208000019425 cirrhosis of liver Diseases 0.000 description 1
• 235000015165 citric acid Nutrition 0.000 description 1
• 238000009833 condensation Methods 0.000 description 1
• 230000005494 condensation Effects 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 229940097362 cyclodextrins Drugs 0.000 description 1
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 206010061428 decreased appetite Diseases 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 125000005265 dialkylamine group Chemical group 0.000 description 1
• 125000005266 diarylamine group Chemical group 0.000 description 1
• 125000004188 dichlorophenyl group Chemical group 0.000 description 1
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 229910001873 dinitrogen Inorganic materials 0.000 description 1
• 230000006806 disease prevention Effects 0.000 description 1
• 239000002612 dispersion medium Substances 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 229940079593 drug Drugs 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 201000008865 drug-induced hepatitis Diseases 0.000 description 1
• 210000001198 duodenum Anatomy 0.000 description 1
• 239000003480 eluent Substances 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 239000002662 enteric coated tablet Substances 0.000 description 1
• 239000002702 enteric coating Substances 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 201000008220 erythropoietic protoporphyria Diseases 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
• 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
• 229940012017 ethylenediamine Drugs 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 208000030533 eye disease Diseases 0.000 description 1
• 208000029944 familial hemophagocytic lymphohistiocytosis type 1 Diseases 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 239000012065 filter cake Substances 0.000 description 1
• 239000000706 filtrate Substances 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 238000003818 flash chromatography Methods 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 125000001153 fluoro group Chemical group F* 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 235000011087 fumaric acid Nutrition 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 229940014259 gelatin Drugs 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 229960002442 glucosamine Drugs 0.000 description 1
• 230000004190 glucose uptake Effects 0.000 description 1
• HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• 231100000283 hepatitis Toxicity 0.000 description 1
• 125000005241 heteroarylamino group Chemical group 0.000 description 1
• 125000005549 heteroarylene group Chemical group 0.000 description 1
• YWGHUJQYGPDNKT-UHFFFAOYSA-N hexanoyl chloride Chemical compound CCCCCC(Cl)=O YWGHUJQYGPDNKT-UHFFFAOYSA-N 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 229960002885 histidine Drugs 0.000 description 1
• 239000008240 homogeneous mixture Substances 0.000 description 1
• XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
• 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
• MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
• HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
• 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 239000012442 inert solvent Substances 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 239000003983 inhalation anesthetic agent Substances 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• 239000012948 isocyanate Substances 0.000 description 1
• 150000002513 isocyanates Chemical class 0.000 description 1
• 229960002725 isoflurane Drugs 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
• ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
• 229940039781 leptin Drugs 0.000 description 1
• 230000003520 lipogenic effect Effects 0.000 description 1
• 239000011344 liquid material Substances 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• LZWQNOHZMQIFBX-UHFFFAOYSA-N lithium;2-methylpropan-2-olate Chemical compound [Li+].CC(C)(C)[O-] LZWQNOHZMQIFBX-UHFFFAOYSA-N 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 229960003646 lysine Drugs 0.000 description 1
• 239000001115 mace Substances 0.000 description 1
• 159000000003 magnesium salts Chemical class 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 235000011090 malic acid Nutrition 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 229960002510 mandelic acid Drugs 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 235000013622 meat product Nutrition 0.000 description 1
• 208000011661 metabolic syndrome X Diseases 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
• 239000004570 mortar (masonry) Substances 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• VZRSXQRHIXTYEL-UHFFFAOYSA-N n-[3-[(3,4-dichlorophenyl)methyl]-4-oxopyrido[2,3-d]pyrimidin-6-yl]-2-phenoxyacetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1C(=O)C2=CC(NC(=O)COC=3C=CC=CC=3)=CN=C2N=C1 VZRSXQRHIXTYEL-UHFFFAOYSA-N 0.000 description 1
• ZZCPRLFJMWBCSV-UHFFFAOYSA-N n-[3-[(3,4-dichlorophenyl)methyl]-4-oxoquinazolin-6-yl]-2-hydroxyacetamide Chemical compound O=C1C2=CC(NC(=O)CO)=CC=C2N=CN1CC1=CC=C(Cl)C(Cl)=C1 ZZCPRLFJMWBCSV-UHFFFAOYSA-N 0.000 description 1
• HGUZQMQXAHVIQC-UHFFFAOYSA-N n-methylethenamine Chemical group CNC=C HGUZQMQXAHVIQC-UHFFFAOYSA-N 0.000 description 1
• 230000009826 neoplastic cell growth Effects 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• 229960003512 nicotinic acid Drugs 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Natural products OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
• JFNLZVQOOSMTJK-KNVOCYPGSA-N norbornene Chemical compound C1[C@@H]2CC[C@H]1C=C2 JFNLZVQOOSMTJK-KNVOCYPGSA-N 0.000 description 1
• 235000021590 normal diet Nutrition 0.000 description 1
• 235000003715 nutritional status Nutrition 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 201000008482 osteoarthritis Diseases 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 239000007800 oxidant agent Substances 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 230000001590 oxidative effect Effects 0.000 description 1
• 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
• NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• 239000012071 phase Substances 0.000 description 1
• 229950000688 phenothiazine Drugs 0.000 description 1
• 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
• UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 239000011574 phosphorus Substances 0.000 description 1
• LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
• 125000005543 phthalimide group Chemical class 0.000 description 1
• 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 235000015320 potassium carbonate Nutrition 0.000 description 1
• 229910000027 potassium carbonate Inorganic materials 0.000 description 1
• 239000012286 potassium permanganate Substances 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 238000011533 pre-incubation Methods 0.000 description 1
• 201000009104 prediabetes syndrome Diseases 0.000 description 1
• 230000035935 pregnancy Effects 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 150000003140 primary amides Chemical class 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 235000019260 propionic acid Nutrition 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 150000003180 prostaglandins Chemical class 0.000 description 1
• 102000004169 proteins and genes Human genes 0.000 description 1
• 108090000623 proteins and genes Proteins 0.000 description 1
• 208000020016 psychiatric disease Diseases 0.000 description 1
• CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
• 230000000541 pulsatile effect Effects 0.000 description 1
• 150000003212 purines Chemical class 0.000 description 1
• PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
• ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical class [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 229940107700 pyruvic acid Drugs 0.000 description 1
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 230000029058 respiratory gaseous exchange Effects 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 230000004141 reverse cholesterol transport Effects 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• 235000003441 saturated fatty acids Nutrition 0.000 description 1
• 150000004671 saturated fatty acids Chemical class 0.000 description 1
• 230000036573 scar formation Effects 0.000 description 1
• 239000012056 semi-solid material Substances 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 239000004208 shellac Substances 0.000 description 1
• ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
• 229940113147 shellac Drugs 0.000 description 1
• 235000013874 shellac Nutrition 0.000 description 1
• 239000000741 silica gel Substances 0.000 description 1
• 229910002027 silica gel Inorganic materials 0.000 description 1
• 238000010898 silica gel chromatography Methods 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 201000009890 sinusitis Diseases 0.000 description 1
• 210000002027 skeletal muscle Anatomy 0.000 description 1
• 239000012312 sodium hydride Substances 0.000 description 1
• 229910000104 sodium hydride Inorganic materials 0.000 description 1
• 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
• 239000011343 solid material Substances 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 235000010356 sorbitol Nutrition 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 238000013222 sprague-dawley male rat Methods 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 239000012058 sterile packaged powder Substances 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
• 235000011149 sulphuric acid Nutrition 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 230000009897 systematic effect Effects 0.000 description 1
• 229940066769 systemic antihistamines substituted alkylamines Drugs 0.000 description 1
• 238000012385 systemic delivery Methods 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• MLGCXEBRWGEOQX-UHFFFAOYSA-N tetradifon Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)C1=CC(Cl)=C(Cl)C=C1Cl MLGCXEBRWGEOQX-UHFFFAOYSA-N 0.000 description 1
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• 229960004559 theobromine Drugs 0.000 description 1
• 230000001225 therapeutic effect Effects 0.000 description 1
• ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 230000037317 transdermal delivery Effects 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 125000005270 trialkylamine group Chemical group 0.000 description 1
• 125000005259 triarylamine group Chemical group 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
• 229960000281 trometamol Drugs 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 239000003039 volatile agent Substances 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 230000004584 weight gain Effects 0.000 description 1
• 235000019786 weight gain Nutrition 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1